Vimarsana
Biggest News Aggregation in the World

Page 6 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Editas Medicine (NASDAQ:EDIT) Coverage Initiated by Analysts at StockNews.com - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report released on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the subject of a number of other research reports. Oppenheimer reissued a market perform rating and set a $12.00 price objective on shares of […]

Source: wkrb13.com
Editas Medicine (NASDAQ:EDIT) Now Covered by Analysts at StockNews.com - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the stock. EDIT has been the topic of a number of other research reports. Raymond James upgraded Editas Medicine from a market perform rating to an outperform rating and […]

FY2023 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Lifted by Cantor Fitzgerald - Vimarsana News

FY2023 EPS Estimates for Editas Medicine, Inc. (NASDAQ:EDIT) Lifted by Cantor Fitzgerald

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Cantor Fitzgerald upped their FY2023 earnings estimates for Editas Medicine in a report issued on Tuesday, August 8th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will post earnings per share of ($2.35) for the year, up from their prior estimate of ($2.43). […]

Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their market perform rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $12.00 price target on the stock. EDIT has been the subject of a number of other research reports. StockNews.com lowered Editas Medicine from a hold […]

Source: wkrb13.com
Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $19.00 - Vimarsana News

Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $19.00

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective cut by Chardan Capital from $22.00 to $19.00 in a report published on Wednesday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. EDIT has been the topic of a number of other reports. Raymond James upgraded shares of Editas Medicine […]